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Background: Despite huge efforts to promote widespread vaccination, measles remains an important cause of
morbidity and mortality worldwide, especially in African children. In March 2011, an abnormally high number of
cases were reported from the Ouham Prefecture, Central African Republic to the national measles case-based
surveillance system. In response, reactive vaccination activities were implemented. The aims of this study were to
investigate this outbreak and describe the response.
Methods: Measles cases were defined according to WHO recommendations. In the first weeks of the outbreak,
blood samples were collected and sent to the Institut Pasteur in Bangui for laboratory confirmation by detection of
IgM antibodies against measles virus. In addition, a portion of viral RNA was amplified from 5 IgM positive patient
samples and the amplicons were sequenced for phylogenetic analysis.
Results: Between March and September 2011, 723 clinical cases originated from the Ouham Prefecture, including 2
deaths, were reported. Amongst 59 blood samples collected, 49 were positive for the detection of IgM. A high
number of self-declared vaccinated subjects (31%) were found amongst the cases. Most of the cases were under
5 years. The causative virus was found to belong to genotype B3.1. In response, 2 sub-national supplementary
immunization activities were quickly conducted and limited this outbreak to mainly 2 sub-prefectures.
Conclusions: This outbreak was the largest epidemic of measles in CAR since 2002. Its occurrence, 3 years after the
last national immunization campaign, highlights the necessity to pursue efforts and improve and extend
immunization programs in order to reach measles elimination goal in Africa.
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Measles is a highly contagious viral disease, which affects
the respiratory system, mostly in children. Although
most people recover within 2–3 weeks, serious com-
plications and even death can occur. In developing
countries, observed high case-fatality rates are due to a
young age at infection, crowding, poor healthcare, mal-
nutrition and underlying immune deficiency (e.g. AIDS)
[1]. There is no specific treatment, but measles can be
prevented by immunization. Huge efforts have been* Correspondence: vianney.tricou@gmail.com
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reproduction in any medium, provided the ormade to promote widespread vaccination, especially in
Africa, where the WHO/UNICEF estimates of im-
munization coverage with a first dose of measles-
containing vaccine (MCV1) provided through routine
infant immunization scheduled at 9 months of age, and
measured by one year of age increased from 56% to 76%
between 2000 and 2010 [2]. During the same period,
Supplementary Immunization Activities (SIA) resulted
in vaccination of approximately half a billion children in
Africa, and the number of measles cases reported
decreased by 62%, from 520,102 in 2000 to 199,174 in
2010 [2,3]. Despite these efforts, measles remains an
important cause of morbidity and mortality worldwide,
especially in African children [4]. Another snag is thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tial progress made towards measles elimination but
where the insufficient vaccination coverage has allowed
for silent accumulation of susceptible individuals [5].
The Central African Republic (CAR), one of the poorest
countries of the world, is affected by political instability
and internal conflicts for more than a decade. In northern
CAR, close to 200,000 persons have been displaced bet-
ween 2005 and 2008 and micro-displacement continues to
this date due to constant insecurity.
In CAR, measles was considered “endemo-epidemic”
until 2005. The total number of reported cases varied
from 3207 in 2000 to 1233 in 2004, then 471 in 2005
[6]. Between 2006 and 2010, number of annually re-
ported cases was low (less than 50 cases per year). Two
campaigns of National Immunization Days (NID) were
held, one catch-up campaign in 2005 targeting children
aged 6 months to 14 years, and one follow-up campaign
in 2008 targeting children between 9 and 59 months.
The estimated vaccination coverage on these campaigns
was 92% and 102%, respectively (unpublished Ministry
of Health data). The WHO/UNICEF estimates of annual
coverage with MCV1 in children under 1 year varied
from 36% in 2000 to 62% in 2010 in CAR [7].
In March 2011, an abnormally high number of clinical
cases were reported in the Ouham Prefecture in northern
CAR by the national measles case-based surveillance sys-
tem (Figure 1). The aims of this study were to investigate
this outbreak and describe the implemented response.
Methods
Ethics statement
This was a non-research national public health surveil-
lance activity approved by the Ministry of Public Health,
Population and the Fight Against AIDS of CAR. Approval
by institutional review board or written informed consent
was not required.
Case definitions and classification
The case-based surveillance requires that every case
presenting with fever and maculopapular rash (i.e. non-
vesicular) and any of the following: cough, coryza (i.e. run-
ny nose) or conjunctivitis (i.e. red eyes) is investigated
and laboratory-tested. Measles surveillance is conducted
through sentinel site reporting. In the Ouham Prefecture,
there were 30 reporting sites (the same of the acute flaccid
paralysis surveillance system). After laboratory-testing 5 to
10 cases closely related in time and space and finding 60%
or more positive, an outbreak is declared and further
laboratory-testing stops and related cases are considered
as epidemiologically linked confirmed. We reviewed infor-
mation about all the cases originated from the Ouham
Prefecture in northern CAR reported to the national mea-
sles case-based surveillance system between March andSeptember 2011. Cases were defined according to WHO
recommendations and classified as suspected, clinical, la-
boratory confirmed, epidemiologically linked confirmed,
clinically compatible or discarded [8].
Laboratory diagnosis and virus genotyping
Blood samples from the first suspected cases were
collected and sent by Médecins Sans Frontières (MSF)
to the Institut Pasteur in Bangui. MSF run the hospitals
of Maitikoulou and Batangafo, and was involved in mea-
sles case-based surveillance by detecting and investiga-
ting the sporadic suspected cases in the area. Laboratory
confirmation was done by detection of IgM antibodies
against measles virus (ELISA, Dade Behring, ref. OWLI15).
Once the Ministry of Public Health, Population and the
Fight Against AIDS of CAR and the WHO declared the
outbreak (following the laboratory confirmation of a
sufficient number of closely related cases), MSF did the
field investigations and participated in the outbreak
response.
In addition, throat, urine and saliva samples were
collected for later virus isolation and genotyping. We
amplified a 526-bp portion of the N gene from 5
samples (3 urine and 2 serum samples) from patients
with IgM antibodies and compared the sequences with
the WHO reference sequences that are recommended
for genotyping [9,10]. Phylogenetic analysis was con-
ducted in MEGA5 [11].
Results
Description of outbreak
In Markounda Sub-prefecture, Ouham Prefecture where
the outbreak started, the index case was an unvaccinated
6-year-old boy from Maitikoulou village. He was admit-
ted on March 10 (epi week 10) to the local health facility
run by MSF. Laboratory confirmation was done by the
Institut Pasteur in Bangui on March 21. A total of 53
suspected measles cases were reported in Maitikoulou
and surroundings between March 3 and April 4 (epi week
9 to 14); 32 (including the index case) were laboratory
confirmed, 9 were epidemiologically linked, and 4 were
clinically compatible cases. No IgM antibody was found
in 7 blood samples, and the corresponding cases were
considered as discarded measles cases (2 were
diagnosed as rubella). Another patient had no rash and
was classified as discarded. A market is weekly held in
Maitikoulou.
During April 2011, the outbreak extended to Bataganfo
Sub-prefecture, Ouham Prefecture which is 157 Km from
Maitikoulou village. Batangafo is an important place for
the trading in the area. The index case was an unvac-
cinated 10-year-old girl, who was admitted on April 3
(epi week 14) to the local hospital run by MSF. The
Institut Pasteur reported laboratory confirmation on
Figure 1 Geographical location of the outbreak (A), and epidemic curve of measles suspected cases (B), Ouham Prefecture, Central
African Republic, 2011. The outbreak took place in the Ouham Prefecture in northern CAR. The main outbreak foci and links between them
are highlighted in red. Suspected cases were reported between the 10th to the 35th epidemiological weeks of 2011. The 2 subnational SIA
conducted from March 28 to April 1, 2011 (epi week 13) in Maitikoulou, Markounda Sub-prefecture (1st SIA) and from April 25 to April 29
(epi week 17), 2011 in Batangafo Sub-prefecture (2nd SIA) were represented by arrows. Blank map has been produced by UNDP on behalf
of the Humanitarian and Development Partnership Team in Central African Republic (HDPT CAR) | Bangui, Central African Republic | 6 May 2008 |
www.hdptcar.net. Map sources are GAUL, SIGCAF, HDPT CAR. Reprinted with the permission from the UNDP. The findings, interpretations and
conclusions are strictly those of the authors and do not necessarily represent the views of UNDP or United Nations Member States.
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Age of cases Total
<1 year 1-4 years 5-14 years ≥15 years
Unknown 4 (1.7%) 15 (7.4%) 19 (12.1%) 4 (3.3%) 42 (5.8%)
Unvaccinated 176 (72.7%) 105 (51.5%) 86 (54.8%) 90 (75.0%) 457 (63.2%)
Vaccinated 62 (25.6 %) 84 (41.2%) 52 (33.1%) 26 (21.7%) 224 (31.0%)
Total 242 204 157 120 723
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the cities of Batangafo and Ouogo and also other
communes or villages in Batangafo Sub-prefecture, of
which 15 were laboratory confirmed. Three cases were
negative for IgM antibodies against measles virus and
considered as discarded cases. The other cases were allFigure 2 Molecular phylogenetic analysis of virus isolates, Ouham Pre
method was used for reconstructing the phylogenetic tree of the N gene s
sequences from the Central African Republic identified in this study (surrou
isolates clustered together in the bootstrap test (1000 replicates) are shownclassified as compatible clinical cases because of difficulties
to fully investigate the epidemiological link due to limited
and overwhelmed medical capacities in a context of hu-
manitarian emergency.
Cases also occurred in 3 other sub-prefectures in
Ouham Prefecture during the same period: 15 cases infecture, Central African Republic, 2011. The neighbor-joining
equences of reference B2 and B3 measles virus strains and new
nded). The percentages of replicate trees in which the associated virus
next to the branches.
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patible), 3 compatible cases in Bossangoa and 1 in Kabo
(laboratory confirmed).
In total, 49 laboratory confirmed, 9 epidemiologically
linked confirmed and 654 clinically compatible cases
were recorded between March and September 2011 in
the Ouham Prefecture. Most of the cases were from 2
sub-prefectures: Markounda and Batangafo at the border
with Chad (Figure 1A). Among the 49 laboratory con-
firmed cases, 7 have been vaccinated within 5 days prior
to sample collection. Most of the children involved were
under 5 years (412/723 i.e. 62%) with a sex ratio of 0.88
(male versus female) (Table 1). The epidemic peak was
reached during the 23rd week, with 98 cases per week
(Figure 1B).
Genotyping
The 5 sequences [GenBank:JQ669934, GenBank:JQ669935,
GenBank:JQ669936, GenBank:JQ669937, GenBank:JQ669-
938] were 100% similar and fell within subgroup B3.1
(Figure 2).
The response
Subnational SIA were conducted from March 28 to
April 1 (epi week 13) in Maitikoulou village, Markounda
Sub-prefecture and from April 25 to April 29 (epi week
17) in Batangafo Sub-prefecture targeting, respectively,
972 and 30 853 children from ages of 9 months to 15
years (Figure 1B). The estimated administrative coverage
was respectively 116% in Maitikoulou, Markounda Sub-
prefecture and 92% in Batangafo Sub-prefecture.
Discussion
This outbreak was the largest epidemic of measles in
CAR since 2002 [12]. The concerned area is regularly
affected by insecurity and people face enormous difficu-
lties in accessing healthcare. Only NGOs like MSF pro-
vide health services to the population in this area.
This epidemic likely occurred because of poor vacci-
nation coverage against measles. Indeed, without high
coverage through routine services and however SIA, the
population of susceptible infants and children rapidly ex-
pand, especially if migrant, and the probability of a large
measles outbreak increases in case of virus reintroduc-
tion [13]. At the same time, a measles outbreak, that
began earlier in 2011, was on-going in neighboring
southern Chad (Logone Occidental Region) [14,15]. The
border between Chad and CAR is porous. Every day,
people cross over this border and some may have
brought measles virus along with them into CAR but
without in-depth case investigations and clear data on
the outbreak that occurred in Chad, it is difficult to con-
clude whether the cases in CAR were endemic or linked
to an importation from Chad. Recent successfulinterruptions of measles transmission in CAR plead in
favor of an importation. Only measles viruses that be-
long to subgroup B3.1 have been found circulating in
CAR since 2002. Data on viral sequence are important
to monitor the strains circulation, especially in absence
of sufficient vaccination pressure, and to show dis-
appearance of existing cluster(s) in case of an outbreak
response.
The high number of vaccinated amongst suspected
cases (224/723 i.e. 31%) can be explained in part by the
inaccurate reporting of vaccination status and by diffi-
culties with ensuring a reliable vaccine cold chain.
The response limited this outbreak mainly to 2 sub-
prefectures but did not stopped the transmission. In
October and November 2011, 10 other laboratory con-
firmed cases occurred in Kabo Sub-prefecture, Ouham
Prefecture, underlining the importance of pursuing efforts
and extend the SIA to a larger area around the center of
the outbreak. To maintain gains in measles control, 95%
routine coverage is required, with periodic NID (every 2–3
years) as recommended by WHO [16]. Surveillance
standards must also be maintained to ensure rapid detec-
tion of measles cases, thus allowing a timely response and
containment.Conclusions
This outbreak was the largest epidemic of measles in
CAR since 2002. Its occurrence, 3 years after the last na-
tional immunization campaign, highlights the necessity
to pursue efforts and improve and extend immunization
programs in order to reach measles elimination goal in
Africa.
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